Aptinyx Net Income 2017-2021 | APTX

Aptinyx net income from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Aptinyx Annual Net Income
(Millions of US $)
2020 $-50
2019 $-57
2018 $-53
2017 $-32
2016 $-15
Aptinyx Quarterly Net Income
(Millions of US $)
2021-09-30 $-21
2021-06-30 $-20
2021-03-31 $-14
2020-12-31 $-11
2020-09-30 $-11
2020-06-30 $-13
2020-03-31 $-15
2019-12-31 $-14
2019-09-30 $-15
2019-06-30 $-12
2019-03-31 $-17
2018-12-31 $-14
2018-09-30 $-14
2018-06-30 $-13
2018-03-31 $-12
2017-12-31
2017-09-30 $-8
2017-06-30 $-8
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.198B $0.002B
Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in clinical stage. Aptinyx Inc. is based in IL, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69